The evaluation and optimal use of rituximab in lymphoid malignancies
Tadeusz Robak1, Pawel Robak2, Piotr Smolewski21Department of Hematology, 2Experimental Hematology, Medical University of Łódź, Łódź, PolandAbstract: Rituximab is an IgG1, chimeric monoclonal antibody (mAb) containing murine light- and heavy-chain variable-region sequenc...
Guardado en:
Autores principales: | Smolewski P, Robak T, Robak P |
---|---|
Formato: | article |
Lenguaje: | EN |
Publicado: |
Dove Medical Press
2012
|
Materias: | |
Acceso en línea: | https://doaj.org/article/f0ea90724741473e8a0a5bb0108a6505 |
Etiquetas: |
Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!
|
Ejemplares similares
-
Lymphoid-biased hematopoietic stem cells and myeloid-biased hematopoietic progenitor cells have radioprotection activity
por: Shanshan Zhang, et al.
Publicado: (2021) -
OUTCOMES OF ALLOGENEIC SC TRANSPLANT IN HEMATOLOGICAL MALIGNANCY PATIENTS USING BUSULFAN 3 (9.6 MG/KG) BASED CONDITIONING REGIMEN
por: Majed Altareb, et al.
Publicado: (2021) -
THE EFFECT OF NIVOLUMAB IN PEDIATRIC MALIGNANT TUMORS: A SINGLE CENTER EXPERIENCE WITH EIGHT PATIENTS
por: Veysel GOK, et al.
Publicado: (2021) -
Multiple myeloma: optimal management and long-term disease control
por: Sriskandarajah P, et al.
Publicado: (2014) -
B-cell malignancies: capture-sequencing strategies for identification of gene rearrangements and translocations into immunoglobulin gene loci
por: Boyle EM, et al.
Publicado: (2014)